Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04951492 · ClinicalTrials.gov registry record · Phase 2
Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04951492 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 2 participants.
The verdict
NCT04951492, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase II trial investigates the effect of olaparib in treating patients with castration resistant prostate adenocarcinoma. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Olaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-11-09 |
| Est. Completion | 2023-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04951492
The ClinicalTrials.gov registry entry for NCT04951492 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Olaparib is the first listed.
NCT04951492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04951492 about?
NCT04951492 is a clinical study titled "Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma". This phase II trial investigates the effect of olaparib in treating patients with castration resistant prostate adenocarcinoma. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT04951492?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2022-11-09. Estimated completion is 2023-10-15.
What interventions are being tested in trial NCT04951492?
The interventions under investigation include: Olaparib (DRUG).
Who is sponsoring clinical trial NCT04951492?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.